All filters
Slidesets
Early transmission steps - Thomas Hope, PhD
Presented at:
International Workshop on HIV Transmission 2015
Slidesets
Safety and pharmacokinetics of quick dissolving polymeric vaginal films delivering antiretroviral combinations for pre-exposure - P. Srinivasan
Presented at:
International Workshop on HIV Transmission 2015
Slidesets
Pre-Exposure Prophylaxis Modality Preferences among Men who Have Sex with Men - E. Hall
Presented at:
International Workshop on HIV Transmission 2015
Meeting
HIV Clinical Forum 2015
Slidesets
Resistance characteristics of Integrase Inhibitors - Charles Boucher, MD, PhD
Presented at:
HIV Clinical Forum 2015
Slidesets
Basic Science of Integrase Inhibitors - François Clavel, MD
Presented at:
HIV Clinical Forum 2015
Slidesets
Pharmacological considerations - Marta Boffito, MD, PhD, FRCP
Presented at:
HIV Clinical Forum 2015
Slidesets
Skills improvement Session 1: Designing clinical trials: Highlights and tips - Alessandro Cozzi-Lepri, PhD
Presented at:
HIV Clinical Forum 2015
Slidesets
Skills improvement Session 2: Analyzing clinical datasets: Challenges and pitfalls - Amanda Mocroft, MD, PhD
Presented at:
HIV Clinical Forum 2015
Slidesets
TDF Use Across the Age Spectrum: From Fetus to Adolescent - Anna Turkova, MD
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Debate: CD4 Assays Are No Longer Needed for Care of Children in Lowresource Countries - Ted Ruel, MD
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
CON ‐ standpoint - Diana Gibb, MD, MRCP, MSc
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Pediatric Treatment Cascade: What Do We Need to Reach “90‐90‐90” for Children - Elaine Abrams, MD
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Virologic Outcomes of Children Switched from Lopinavir/Ritonavir‐ to Efavirenz‐Based Antiretroviral Treatment: a retrospective cohort study - Kirsten Reichmuth
Presented at:
International Workshop on HIV & Pediatrics 2015
Slidesets
Lopinavir ritonavir (1:1 ratio) in the presence of rifampicin is not inferior to lopinavir ritonavir (4:1 ratio) in the absence of rifampicin in HIV children. Interim analysis of an open label sequential non- randomized phar- Mark Cotton
Presented at:
International Workshop on HIV & Pediatrics 2015